Key PointsQuestionWhat is the most appropriate primary end point in phase 2 trials of checkpoint inhibitors? FindingsIn this systematic review and meta-analysis of phase 2 and phase 3 trials of checkpoint inhibitors in advanced solid cancers, response rate correlated poorly with overall survival, but 6-month progression-free survival was a better predictor of 12-month overall survival. MeaningSix-month progression-free survival is recommended in place of response rate as an end point in future phase 2 checkpoint-inhibitor trials.
JAMA Oncology – American Medical Association
Published: Apr 22, 2018
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera